Profound Medical Corp. is a medical technology company. It is focused on a therapeutics platform which provides the precision of real-time Magnetic Resonance Imaging technology for the incision-free ablation of diseased tissue. The company principally commercialized the TULSA-PRO(R) and Sonalleve(R) platforms. Profound Medical Corp. is based in Mississauga, Canada.
| Revenue (Most Recent Fiscal Year) | $10.68M |
| Net Income (Most Recent Fiscal Year) | $-27.82M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 13.50 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.15 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -269.38% |
| Net Margin (Trailing 12 Months) | -269.35% |
| Return on Equity (Trailing 12 Months) | -70.41% |
| Return on Assets (Trailing 12 Months) | -57.22% |
| Current Ratio (Most Recent Fiscal Quarter) | 11.31 |
| Quick Ratio (Most Recent Fiscal Quarter) | 10.03 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.09 |
| Inventory Turnover (Trailing 12 Months) | 0.60 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.69 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.36 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.12 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.22 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 30.05M |
| Free Float | 29.60M |
| Market Capitalization | $160.18M |
| Average Volume (Last 20 Days) | 0.08M |
| Beta (Past 60 Months) | 0.44 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.52% |
| Percentage Held By Institutions (Latest 13F Reports) | 47.86% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |